Intracellular and nuclear melatonin-binding sites (ROR/NQO2/CaM)

Intracellular and nuclear melatonin-binding sites represent a diverse group of non-membrane proteins that mediate the pleiotropic effects of melatonin beyond its classical G protein-coupled receptors (MT1 and MT2). The primary components include the retinoid-related orphan receptor (ROR) family, particularly RORα and RORβ, which function as ligand-dependent transcription factors, and the enzyme quinone reductase 2 (NQO2), historically identified as the MT3 binding site. Additionally, melatonin interacts with intracellular calcium-binding proteins such as calmodulin and calreticulin to modulate cellular signaling and cytoskeletal dynamics. These binding sites are critical for regulating circadian rhythms, enhancing antioxidant defenses, and modulating immune and inflammatory responses. In clinical contexts, these targets are implicated in the pathophysiology of various diseases, including cancer, where they influence tumor cell proliferation and apoptosis, and neurodegenerative disorders, where they provide neuroprotection against oxidative stress. Pharmacological agents like ROR agonists (e.g., CGP 52608) and NQO2 inhibitors (e.g., resveratrol) are being explored for their therapeutic potential in treating sleep disorders, autoimmune conditions, and metabolic syndromes. However, the broad distribution and complex signaling crosstalk of these sites pose significant challenges for achieving high drug specificity and minimizing off-target effects.

Other names

Nuclear melatonin receptorMT3 binding siteRetinoid-related orphan receptor (ROR)Retinoid Z receptor (RZR)Quinone reductase 2 (NQO2)Calmodulin-binding siteML2 receptor

Melatonin acts through these sites via multiple mechanisms: it binds to nuclear receptors (RORα/β) to regulate the transcription of genes involved in immunity and circadian rhythms; it inhibits the enzyme quinone reductase 2 (NQO2/MT3) to modulate redox homeostasis and oxidative stress; and it binds to calmodulin to antagonize calcium-dependent signaling pathways.